关于Ramucirumab用于转移性胃癌的二线治疗的现实数据:罗马尼亚人口的两中心研究
Diana Galos1, Loredana Balacescu2, Radu Vidra3,4
1Department of Medical Oncology, The Oncology Institute Prof. Dr. Ion Chiricuţă, 400015 Cluj-Napoca, Romania.
Life (Basel, Switzerland)
|December 23, 2023
概括
在罗马尼亚的患者中,Ramucirumab是晚期胃癌的标准治疗方法,在罗马尼亚患者中显示出有效性和可管理的安全性. 现实世界的数据证实了其在改善无进展生存率方面的有效性.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
- 临床药理学 临床药理学
背景情况:
- 拉慕西鲁马布是基于RAINBOW和REGARD试验的高级/转移性胃或胃食道结 (GEJ) 癌症的标准二线治疗方法.
- 它的使用被批准单独使用或与帕克利塔塞尔一起使用.
研究的目的:
- 在现实临床环境中,评估ramucirumab在罗马尼亚人口中的疗效和安全性.
- 评估ramucirumab单一治疗与与帕克利塔塞尔联合治疗.
主要方法:
- 一项回顾性观察性研究,涉及69名转移性胃癌和GEJ癌症患者,他们在2018-2022年期间接受治疗.
- 患者接受了拉慕西鲁马布单独治疗 (18名患者) 或拉慕西鲁马布加帕克利塔塞尔 (51名患者).
- 终点包括中位数无进展生存 (PFS),总生存 (OS) 和不良事件 (AE).
主要成果:
- 最常见的RAMUCIRUMAB加PACLITAXEL的AE是血液毒性;疲劳和头痛是最常见的RAMUCIRUMAB单独治疗.
- 中位数PFS为4.7个月,中位数OS为18.23个月.
- PFS与治疗周期,ECOG状态和转移部位相关;OS与治疗周期和HER2状态相关.
结论:
- 结果支持单独或与帕克利塔塞尔一起使用的拉穆齐鲁马布已知的毒性概况.
- 该研究表明,在评估的罗马尼亚患者队列中,PFS的中位数相对较高.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...